Rothschild & Co Upgrades Abbott Laboratories to Buy, Raises Price Target to $127
Rothschild & Co analyst Ed Ridley-Day upgrades Abbott Laboratories (NYSE:ABT) from Neutral to Buy and raises the price target from $119 to $127.
Share
Why It Matters
An expert called Abbott Laboratories a good buy and raised the target price higher. This suggests the company looks stronger to this analyst than before.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.